BibTex format
@article{Chadeau-Hyam:2022:10.1016/s2213-2600(21)00542-7,
author = {Chadeau-Hyam, M and Wang, H and Eales, O and Haw, D and Bodinier, B and Whitaker, M and Walters, CE and Ainslie, KEC and Atchison, C and Fronterre, C and Diggle, PJ and Page, AJ and Trotter, AJ and Ashby, D and Barclay, W and Taylor, G and Cooke, G and Ward, H and Darzi, A and Riley, S and Donnelly, CA and Elliott, P and Chadeau, M and Wang, H and Eales, O and Haw, D and Bodinier, B and Whitaker, M and Walters, C and Ainslie, K and Atchison, C and Fronterre, C and Diggle, P and Page, A and Trotter, A and Ashby, D and Barclay, W and Taylor, G and Cooke, G and Ward, H and Darzi, A and Riley, S and Donnelly, C and Elliott, P},
doi = {10.1016/s2213-2600(21)00542-7},
journal = {The Lancet Respiratory Medicine},
pages = {355--366},
title = {SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys},
url = {http://dx.doi.org/10.1016/s2213-2600(21)00542-7},
volume = {10},
year = {2022}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - SummaryBackground England has experienced a third wave of the COVID-19 epidemic since the end of May, 2021, coincidingwith the rapid spread of the delta (B.1.617.2) variant, despite high levels of vaccination among adults. Vaccinationrates (single dose) in England are lower among children aged 16–17 years and 12–15 years, whose vaccination inEngland commenced in August and September, 2021, respectively. We aimed to analyse the underlying dynamicsdriving patterns in SARS-CoV-2 prevalence during September, 2021, in England.Methods The REal-time Assessment of Community Transmission-1 (REACT-1) study, which commenced datacollection in May, 2020, involves a series of random cross-sectional surveys in the general population of Englandaged 5 years and older. Using RT-PCR swab positivity data from 100 527 participants with valid throat and noseswabs in round 14 of REACT-1 (Sept 9–27, 2021), we estimated community-based prevalence of SARS-CoV-2 andvaccine effectiveness against infection by combining round 14 data with data from round 13 (June 24 to July 12, 2021;n=172 862).Findings During September, 2021, we estimated a mean RT-PCR positivity rate of 0·83% (95% CrI 0·76–0·89), with areproduction number (R) overall of 1·03 (95% CrI 0·94–1·14). Among the 475 (62·2%) of 764 sequenced positiveswabs, all were of the delta variant; 22 (4·63%; 95% CI 3·07–6·91) included the Tyr145His mutation in the spikeprotein associated with the AY.4 sublineage, and there was one Glu484Lys mutation. Age, region, key worker status,and household size jointly contributed to the risk of swab positivity. The highest weighted prevalence was observedamong children aged 5–12 years, at 2·32% (95% CrI 1·96–2·73) and those aged 13–17 years, at 2·55% (2·11–3·08).The SARS-CoV-2 epidemic grew in those aged 5–11 years, with an R of 1&m
AU - Chadeau-Hyam,M
AU - Wang,H
AU - Eales,O
AU - Haw,D
AU - Bodinier,B
AU - Whitaker,M
AU - Walters,CE
AU - Ainslie,KEC
AU - Atchison,C
AU - Fronterre,C
AU - Diggle,PJ
AU - Page,AJ
AU - Trotter,AJ
AU - Ashby,D
AU - Barclay,W
AU - Taylor,G
AU - Cooke,G
AU - Ward,H
AU - Darzi,A
AU - Riley,S
AU - Donnelly,CA
AU - Elliott,P
AU - Chadeau,M
AU - Wang,H
AU - Eales,O
AU - Haw,D
AU - Bodinier,B
AU - Whitaker,M
AU - Walters,C
AU - Ainslie,K
AU - Atchison,C
AU - Fronterre,C
AU - Diggle,P
AU - Page,A
AU - Trotter,A
AU - Ashby,D
AU - Barclay,W
AU - Taylor,G
AU - Cooke,G
AU - Ward,H
AU - Darzi,A
AU - Riley,S
AU - Donnelly,C
AU - Elliott,P
DO - 10.1016/s2213-2600(21)00542-7
EP - 366
PY - 2022///
SN - 2213-2600
SP - 355
TI - SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys
T2 - The Lancet Respiratory Medicine
UR - http://dx.doi.org/10.1016/s2213-2600(21)00542-7
UR - https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00542-7/fulltext
UR - http://hdl.handle.net/10044/1/93140
VL - 10
ER -
